Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13

 

 Permissions and Reprints

Abstract

Von Willebrand factor (VWF) is one of the most important proteins of the hemostatic system. Its multimeric state is essential for its natural function to guide platelets to sites of injury. ADAMTS13 is the key protease that regulates the multimeric state of VWF. Without ADAMTS13, VWF multimers can grow to pathologically large sizes. This is a risk factor for the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this condition, VWF-rich thrombi occlude the microvasculature of various tissues. Intriguingly, a complete ADAMTS13 deficiency does not cause continuous TTP, either in patients or genetically targeted mice. Instead, TTP occurs in episodes of disease, separated by extended periods of remission. This indicates that regulating factors beyond ADAMTS13 are likely involved in this pathologic cascade of events. This raises the question of what really happens when ADAMTS13 is (temporarily) unavailable. In this review, we explore the possible role of complementary mechanisms that are capable of modifying the thrombogenic potential of VWF.

• References

• 1 Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood 2014; 124 (9) 1412-1425
  CrossrefPubMedGoogle Scholar
• 2 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371 (19) 1847-1848
  PubMedGoogle Scholar
• 3 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
  CrossrefPubMedGoogle Scholar
• 4 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
  CrossrefPubMedGoogle Scholar
• 5 Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98 (6) 1654-1661
  CrossrefPubMedGoogle Scholar
• 6 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6) 1662-1666
  CrossrefPubMedGoogle Scholar
• 7 Crawley JTB, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118 (12) 3212-3221
  CrossrefPubMedGoogle Scholar
• 8 Tersteeg C, Schiviz A, De Meyer SF , et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2015; ; DOI: ATVBAHA.115.306014.
  PubMedGoogle Scholar
• 9 Schiviz A, Wuersch K, Piskernik C , et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012; 119 (25) 6128-6135
  CrossrefPubMedGoogle Scholar
• 10 Jian C, Xiao J, Gong L , et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119 (16) 3836-3843
  CrossrefPubMedGoogle Scholar
• 11 Li GW, Rambally S, Kamboj J , et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion 2014; 54 (5) 1221-1224
  CrossrefPubMedGoogle Scholar
• 12 Shortt J, Opat SS, Wood EM. N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?. Transfusion 2014; 54 (9) 2362-2363
  CrossrefPubMedGoogle Scholar
• 13 Callewaert F, Roodt J, Ulrichts H , et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120 (17) 3603-3610
  CrossrefPubMedGoogle Scholar
• 14 Feys HB, Roodt J, Vandeputte N , et al. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012; 120 (17) 3611-3614
  CrossrefPubMedGoogle Scholar
• 15 Holz JB. The TITAN trial—assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apheresis Sci 2012; 46 (3) 343-346
  CrossrefPubMedGoogle Scholar
• 16 Peyvandi F, Scully M, Knobl P , et al. Additional data from the titan trial with the anti-VWF nanobody caplacizumab in the treatment of acquired TTP. J Thromb Haemost 2015; 13 (2) LB006
  PubMedGoogle Scholar
• 17 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
  CrossrefPubMedGoogle Scholar
• 18 Rieger M, Mannucci PM, Kremer Hovinga JA , et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106 (4) 1262-1267
  CrossrefPubMedGoogle Scholar
• 19 Lotta LA, Wu HM, Mackie IJ , et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120 (2) 440-448
  CrossrefPubMedGoogle Scholar
• 20 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14 (2) 437-454
  CrossrefPubMedGoogle Scholar
• 21 Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115 (8) 1500-1511 , quiz 1662
  CrossrefPubMedGoogle Scholar
• 22 Peyvandi F, Lavoretano S, Palla R , et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93 (2) 232-239
  CrossrefPubMedGoogle Scholar
• 23 Motto DG, Chauhan AK, Zhu G , et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115 (10) 2752-2761
  CrossrefPubMedGoogle Scholar
• 24 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris) 2015; 63 (3) 136-143
  CrossrefPubMedGoogle Scholar
• 25 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91 (1) 1-19
  CrossrefPubMedGoogle Scholar
• 26 Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120 (6) 1157-1164
  CrossrefPubMedGoogle Scholar
• 27 Brinkmann V, Reichard U, Goosmann C , et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303 (5663) 1532-1535
  CrossrefPubMedGoogle Scholar
• 28 Clark SR, Ma AC, Tavener SA , et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13 (4) 463-469
  CrossrefPubMedGoogle Scholar
• 29 Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32 (8) 1777-1783
  CrossrefPubMedGoogle Scholar
• 30 Demers M, Krause DS, Schatzberg D , et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012; 109 (32) 13076-13081
  CrossrefPubMedGoogle Scholar
• 31 Thomas GM, Carbo C, Curtis BR , et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 2012; 119 (26) 6335-6343
  CrossrefPubMedGoogle Scholar
• 32 Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood 2014; 123 (24) 3818-3827
  CrossrefPubMedGoogle Scholar
• 33 Borissoff JI, Joosen IA, Versteylen MO , et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33 (8) 2032-2040
  CrossrefPubMedGoogle Scholar
• 34 Fuchs TA, Alvarez JJ, Martinod K, Bhandari AA, Kaufman RM, Wagner DD. Neutrophils release extracellular DNA traps during storage of red blood cell units. Transfusion 2013; 53 (12) 3210-3216
  CrossrefPubMedGoogle Scholar
• 35 von Brühl ML, Stark K, Steinhart A , et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (4) 819-835
  CrossrefPubMedGoogle Scholar
• 36 Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31 (6) E1445-E1460
  CrossrefPubMedGoogle Scholar
• 37 Zipfel PF, Edey M, Heinen S , et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3 (3) e41
  CrossrefPubMedGoogle Scholar
• 38 Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40 (5) 544-550
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 Feng S, Liang X, Cruz MA , et al. The interaction between factor H and von Willebrand factor. PLoS ONE 2013; 8 (8) e73715
  CrossrefPubMedGoogle Scholar
• 40 Rayes J, Roumenina LT, Dimitrov JD , et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014; 123 (1) 121-125
  CrossrefPubMedGoogle Scholar
• 41 Nolasco L, Nolasco J, Feng S, Afshar-Kharghan V, Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers—brief report. Arterioscler Thromb Vasc Biol 2013; 33 (11) 2524-2528
  CrossrefPubMedGoogle Scholar
• 42 Wohner N, Kovács A, Machovich R, Kolev K. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways. Thromb Res 2012; 129 (4) e41-e46
  CrossrefPubMedGoogle Scholar
• 43 Raife TJ, Cao W, Atkinson BS , et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114 (8) 1666-1674
  CrossrefPubMedGoogle Scholar
• 44 Hollestelle MJ, Sprong T, Bovenschen N , et al. von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease. J Thromb Haemost 2010; 8 (5) 1098-1106
  PubMedGoogle Scholar
• 45 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (1) 93-100
  CrossrefPubMedGoogle Scholar
• 46 Mikes B, Sinkovits G, Farkas P , et al. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. Thromb Res 2014; 133 (4) 616-621
  CrossrefPubMedGoogle Scholar
• 47 Budde U, Schneppenheim R. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura. Hamostaseologie 2014; 34 (3) 215-225
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Buzza MS, Dyson JM, Choi H , et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J Biol Chem 2008; 283 (33) 22498-22504
  CrossrefPubMedGoogle Scholar
• 49 Hollestelle MJ, Lai KW, van Deuren M , et al. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS ONE 2011; 6 (9) e24216
  CrossrefPubMedGoogle Scholar
• 50 Wensink AC, Hack CE, Bovenschen N. Granzymes regulate proinflammatory cytokine responses. J Immunol 2015; 194 (2) 491-497
  CrossrefPubMedGoogle Scholar
• 51 Chandler WL, Jelacic S, Boster DR , et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346 (1) 23-32
  CrossrefPubMedGoogle Scholar
• 52 Monteagudo J, Pereira A, Reverter JC , et al. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Thromb Haemost 1991; 66 (5) 515-519
  PubMedGoogle Scholar
• 53 Raife T, Friedman KD, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004; 92 (2) 387-393
  PubMedGoogle Scholar
• 54 Wada H, Mori Y, Shimura M , et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998; 58 (3) 189-194
  CrossrefPubMedGoogle Scholar
• 55 Sagripanti A, Carpi A, Baicchi U , et al. Plasmatic parameters of coagulation activation in thrombotic microangiopathy. Biomed Pharmacother 1996; 50 (8) 357-362
  CrossrefPubMedGoogle Scholar
• 56 Takahashi H, Tatewaki W, Wada K, Shibata A. Thrombin generation in patients with thrombotic thrombocytopenic purpura. Am J Hematol 1989; 32 (4) 255-257
  CrossrefPubMedGoogle Scholar
• 57 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257 (6) 2912-2919
  PubMedGoogle Scholar
• 58 Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266 (19) 12752-12758
  PubMedGoogle Scholar
• 59 Miles LA, Parmer RJ. Plasminogen receptors: the first quarter century. Semin Thromb Hemost 2013; 39 (4) 329-337
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985; 76 (1) 261-270
  CrossrefPubMedGoogle Scholar
• 61 Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79 (1) 38-44
  PubMedGoogle Scholar
• 62 Feys HB, Vandeputte N, Palla R , et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (9) 2053-2062
  CrossrefPubMedGoogle Scholar
• 63 Crawley JTB, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105 (3) 1085-1093
  PubMedGoogle Scholar
• 64 Tersteeg C, de Maat S, De Meyer SF , et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 2014; 129 (12) 1320-1331
  CrossrefPubMedGoogle Scholar
• 65 Kakishita E, Koyama T, Higuchi M, Kunitomi O, Oura Y, Nagai K. Fibrinogenolysis in thrombotic thrombocytopenic purpura. Am J Hematol 1989; 32 (1) 14-19
  CrossrefPubMedGoogle Scholar
• 66 Hoirisch-Clapauch S, Nardi AE. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura. Med Hypotheses 2014; 83 (6) 747-750
  CrossrefPubMedGoogle Scholar
• 67 Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VW. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 2000; 96 (8) 2775-2783
  PubMedGoogle Scholar
• 68 Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998; 91 (9) 3300-3307
  PubMedGoogle Scholar
• 69 Xu Y, Hagege J, Mougenot B, Sraer JD, Rønne E, Rondeau E. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 1996; 50 (6) 2011-2019
  CrossrefPubMedGoogle Scholar
• 70 Bu F, Maga T, Meyer NC , et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014; 25 (1) 55-64
  CrossrefPubMedGoogle Scholar
• 71 Hugenholtz GCG, Lisman T. Letter by Hugenholtz and Lisman regarding article, “plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.”. Circulation 2015; 131 (2) e18
  CrossrefPubMedGoogle Scholar
• 72 Sinnaeve PR, Armstrong PW, Gershlick AH , et al; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation 2014; 130 (14) 1139-1145
  CrossrefPubMedGoogle Scholar
• 73 Vandelli L, Marietta M, Gambini M , et al. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015; 24 (2) 394-400
  CrossrefPubMedGoogle Scholar
• 74 Vesconi S, Langer M, Rossi E, Donati MB. Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura. Haemostasis 1981; 10 (5) 289-295
  PubMedGoogle Scholar
• 75 Wang X, Palasubramaniam J, Gkanatsas Y , et al. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res 2014; 114 (7) 1083-1093
  CrossrefPubMedGoogle Scholar